nach oben

Basic Research in Cardiology

Erschienen in:

01.09.2008 | MEETING REPORT

Clinical translation of cardioprotective strategies

Report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection

verfasst von: Derek J. Hausenloy, Prof. Derek M. Yellon

Erschienen in: Basic Research in Cardiology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Excerpt

The 5th Hatter Institute International Workshop on Cardioprotection was held in South Africa in April of this year. Leading experts in the field of cardioprotection assembled to discuss and debate the recent developments in this exciting area of research, focusing primarily on the translation of novel experimental cardioprotective strategies into clinical therapy. Interest in the early myocardial reperfusion phase as a target for cardioprotection has been regenerated by the publication of several small high-profile ‘proof-of-concept’ clinical studies on cardioprotection [3, 5, 31, 32, 47, 48]. …

Aletras AH, Kellman P, Derbyshire JA, Arai AE (2008) ACUT(2)E TSE-SSFP: a hybrid method for T2-weighted imaging of edema in the heart. Magn Reson Med 59:229–235PubMedCrossRef

Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF Jr, Arai AE (2006) Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 113:1865–1870PubMedCrossRef

Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME (2007) Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 116:I98–105PubMedCrossRef

Apstein CS, Opie LH (2005) A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J 26:956–959PubMedCrossRef

Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P (2008) Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117:886–896PubMedCrossRef

Baxter GF, Yellon DM (2003) Current trends and controversies in ischemia-reperfusion research–meeting report of the Hatter institute 3rd international workshop on cardioprotection. Basic Res Cardiol 98:133–136PubMedCrossRef

Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen DJ (2008) Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 155:817–822PubMedCrossRef

Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R (2008) Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102:131–135PubMedCrossRef

Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA (2004) Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95:125–134PubMedCrossRef

10.

Bose AK, Mocanu MM, Carr RD, Yellon DM (2005) Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19:9–11PubMedCrossRef

11.

Burley DS, Hamid SA, Baxter GF (2007) Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev 12:279–291PubMedCrossRef

12.

Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, Li J, Holtby HM, Cox PN, Smallhorn JF, Van Arsdell GS, Redington AN (2006) Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 47:2277–2282PubMedCrossRef

13.

Cohen MV, Downey JM (2008) Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103:203–215PubMedCrossRef

14.

Ferdinandy P, Schulz R, Baxter GF (2007) Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59:418–458PubMedCrossRef

15.

Forster K, Paul I, Solenkova N, Staudt A, Cohen MV, Downey JM, Felix SB, Krieg T (2006) NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res Cardiol 101:319–326PubMedCrossRef

16.

Fuglesteg BN, Suleman N, Tiron C, Kanhema T, Lacerda L, Andreasen TV, Sack MN, Jonassen AK, Mjos OD, Opie LH, Lecour S (2008) Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion. Basic Res Cardiol [Epub ahead of print]

17.

Galie N, Guarnieri C, Ussia GP, Zimarino M, Traini AM, Parlangeli R, Vaona I, Branzi A, Magnani B (1995) Limitation of myocardial infarct size by nicorandil after sustained ischemia in pigs. J Cardiovasc Pharmacol 26:477–484PubMedCrossRef

18.

Gomez L, Thibault H, Gharib A, Dumont JM, Vuagniaux G, Scalfaro P, Derumeaux G, Ovize M (2007) Inhibition of mitochondrial permeability transition improves functional recovery and reduces mortality following acute myocardial infarction in mice. Am J Physiol Heart Circ Physiol 293:H1654–H1661PubMedCrossRef

19.

Hausenloy DJ, Duchen MR, Yellon DM (2003) Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60:617–625PubMedCrossRef

20.

Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM (2002) Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 55:534–543PubMedCrossRef

21.

Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM (2007) Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 370:575–579PubMedCrossRef

22.

Hausenloy DJ, Yellon DM (2003) The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35:339–341PubMedCrossRef

23.

Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61:448–460PubMedCrossRef

24.

Hausenloy DJ, Yellon DM (2005) Protecting the myocardium at time of reperfusion–meeting report of the Hatter institute 4th international workshop on cardio-protection. Basic Res Cardiol 100:383–386PubMedCrossRef

25.

Hausenloy DJ, Yellon DM (2007a) Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116:173–191PubMedCrossRef

26.

Hausenloy DJ, Yellon DM (2007b) Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12:217–234PubMedCrossRef

27.

Hausenloy DJ, Yellon DM (2008) Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res May 20. [Epub ahead of print]

28.

Heusch G, Schulz R (2002) Remote preconditioning. J Mol Cell Cardiol 34:1279–1281PubMedCrossRef

29.

Imagawa J, Baxter GF, Yellon DM (1998) Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol 31:74–79PubMedCrossRef

30.

Kerendi F, Kin H, Halkos ME, Jiang R, Zatta AJ, Zhao ZQ, Guyton RA, Vinten-Johansen J (2005) Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 100:404–412PubMedCrossRef

31.

Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S (2007) Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370:1483–1493PubMedCrossRef

32.

Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW (2006) Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 27:2400–2405PubMedCrossRef

33.

Kloner RA, Rezkalla SH (2004) Cardiac protection during acute myocardial infarction: where do we stand in 2004? J Am Coll Cardiol 44:276–286PubMedCrossRef

34.

Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, Opie LH (2005) Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (akt and extracellular signal-regulated kinase). Circulation 112:3911–3918PubMedCrossRef

35.

Lehrke S, Steen H, Sievers HH, Peters H, Opitz A, Muller-Bardorff M, Wiegand UK, Katus HA, Giannitsis E (2004) Cardiac troponin T for prediction of short- and long-term morbidity and mortality after elective open heart surgery. Clin Chem 50:1560–1567PubMedCrossRef

36.

Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the acute myocardial infarction study of adenosine (AMISTAD) trial. J Am Coll Cardiol 34:1711–1720PubMedCrossRef

37.

Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L (2005) Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 293:437–446PubMedCrossRef

38.

Miki T, Miura T, Tanno M, Nishihara M, Naitoh K, Sato T, Takahashi A, Shimamoto K (2007) Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol 102:163–170PubMedCrossRef

39.

Ndrepepa G, Mehilli J, Schwaiger M, Schuhlen H, Nekolla S, Martinoff S, Schmitt C, Dirschinger J, Schomig A, Kastrati A (2004) Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. J Nucl Med 45:725–729PubMed

40.

Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962–965PubMedCrossRef

41.

O’Neill WW (2003) Cooling as an adjunct to primary PCI for myocardial infarction. Transcatheter cardiovascular therapeutics conference

42.

Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P (1993) Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87:893–899PubMed

43.

Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29:258–267PubMedCrossRef

44.

Riksen NP, Rongen GA, Yellon D, Smits P (2008) Human in vivo research on the vascular effects of adenosine. Eur J Pharmacol 585:220–227PubMedCrossRef

45.

Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW (2005) A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45:1775–1780PubMedCrossRef

46.

Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G (2006) Coronary microembolization. Basic Res Cardiol 101:373–382PubMedCrossRef

47.

Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M (2005) Postconditioning the human heart. Circulation 112:2143–2148PubMedCrossRef

48.

Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, Andre-Fouet X, Macia JC, Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, Ovize M (2008) Long-term benefit of postconditioning. Circulation 117:1037–1044PubMedCrossRef

49.

Warda HM, Bax JJ, Bosch JG, Atsma DE, Jukema JW, van der Wall EE, van der LA, Schalij MJ, Oemrawsingh PV (2005) Effect of intracoronary aqueous oxygen on left ventricular remodeling after anterior wall ST-elevation acute myocardial infarction. Am J Cardiol 96:22–24PubMedCrossRef

50.

Yang XM, Philipp S, Downey JM, Cohen MV (2006) Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 101:311–318PubMedCrossRef

51.

Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135PubMedCrossRef

Titel: Clinical translation of cardioprotective strategies
Report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection
verfasst von: Derek J. Hausenloy
Prof. Derek M. Yellon
Publikationsdatum: 01.09.2008
Verlag: D. Steinkopff-Verlag
Erschienen in: Basic Research in Cardiology / Ausgabe 5/2008
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-008-0736-x

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical translation of cardioprotective strategies

Report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection

Excerpt

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

NO and PGI2 in coronary endothelial dysfunction in transgenic mice with dilated cardiomyopathy

Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts

Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion

Persistent beneficial effect of postconditioning against infarct size: role of mitochondrial KATP channels during reperfusion

Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction

The role of inflammatory cytokines in endothelial dysfunction

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie